ContractStudy Tripartite Agreement Smlouva O Klinickém Hodnocení • April 22nd, 2024
CLINICAL STUDY TRIPARTITE AGREEMENT SMLOUVA O KLINICKÉM HODNOCENÍ This clinical study agreement (“Agreement”), effective as of date of publication in the Register of Contracts (the “Effective Date”), is entered into by and between(1) Pierre Fabre Medicament, a company incorporated in France under company registration number 326118502 with its principal office and place of business at 45, Place Abel Gance, F-92100 Boulogne, France (“Sponsor”);(2) Fakultní nemocnice Olomouc, a clinical research site with its principal office and place of business at I.P. Pavlova 6, 775 20 Olomouc, Czech Republic, IN: 00098892, VAT IN: CZ00098892 (“Institution”);(3) with his placeof business at Fakultní nemocnice Olomouc, I. P. Pavlova 185/6, Olomouc, 779 00, Czech Republic, Principal Investigator (“PI”) individually referred to as a “Party” and collectively as “Parties”). The Study shall be carried out in Onkologická klinika of the Institutionled by the PI. The Parties acknowledge that Cmed (Clinical Res
